Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14890298 | 0.85 | MEN1 (0.67) | KMT2AMEN1NPSR1ALDH1A1MAPT | |
| SCHEMBL6706698 | 0.83 | ALDH1A1 (0.79) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL21467806 | 0.81 | ALDH1A1 (1.00) | KMT2AMEN1NPSR1ALDH1A1MAPT | |
| SCHEMBL7817352 | 0.81 | MAPT (0.71) | KMT2AMEN1NPSR1ALDH1A1MAPT | |
| SCHEMBL10046484 | 0.80 | MEN1 (0.64) | KMT2AMEN1NPSR1ALDH1A1MAPT | |
| SCHEMBL10046487 | 0.79 | GAA (0.73) | KMT2AMEN1NPSR1ALDH1A1MAPT | |
| SCHEMBL15347000 | 0.79 | ATM (0.59) | KMT2AMEN1NPSR1ALDH1A1MAPT | |
| SCHEMBL7946942 | 0.77 | ALDH1A1 (0.72) | KMT2AMEN1NPSR1ALDH1A1MAPT | |
| SCHEMBL12503135 | 0.77 | LMNA (0.79) | KMT2AMEN1NPSR1ALDH1A1MAPT | |
| SCHEMBL10046616 | 0.77 | ATM (0.57) | KMT2AMEN1NPSR1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170370929-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE DELTA-OPIOID RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-28 | — | — | US | disclosed |
| WO-2016100605-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE DELTA-OPIOID RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-23 | — | — | WO | disclosed |
| US-8906416-B2 | Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2014-12-09 | — | — | US | disclosed |
| US-8906416-B2 | Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2014-12-09 | — | — | US | disclosed |
| US-8906416-B2 | Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2014-12-09 | — | — | US | disclosed |
| US-20130108568-A1 | XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2013-05-02 | — | — | US | disclosed |
| US-20130108568-A1 | XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2013-05-02 | — | — | US | disclosed |
| US-20130108568-A1 | XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004390-A1 | XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130108568-A1 | XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS | ACOX3, CBR3, GALR3 | KMT2A 4312/4885MEN1 2682/4885NPSR1 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.